Skip to main content
. Author manuscript; available in PMC: 2022 Mar 12.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2021 Jul 4;21(11):e895–e902. doi: 10.1016/j.clml.2021.06.022

Table 2:

ALL Diagnosis and Initial Treatment

Disease Subtype, n (%)
Pre-B 127 87%
T cell 18 12%
CML/Lymphoid BC 1 1%
Ph+ Karyotype 30 24%
CD20+ Immunophenotype 68 54%
Induction Chemotherapy
Hyper-CVAD ± Rituximab 87 59%
Augmented hyper-CVAD 17 12%
Hyper-CVAD + TKI 30 21%
Augmented BFM, Linker, other 9 6%
None 3 2%

Abbreviations: ALL = acute lymphoblastic leukemia; Pre-B = precursor B; CML = chronic myeloid leukemia; BC = blast crisis; Ph = Philadelphia chromosome; hyper-CVAD = hyperfractionated cyclophosphamide, doxorubicin, vincristine and dexamethasone alternating with methotrexate and high-dose cytarabine; BFM = Berlin-Frankfurt-Munich.